Thu, Aug 21, 2014, 10:27 AM EDT - U.S. Markets close in 5 hrs 33 mins

Recent

% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

racavalli 176 posts  |  Last Activity: 11 hours ago Member since: Jul 31, 2012
  • racavalli racavalli Jul 31, 2014 2:54 PM Flag

    go to BLGO website and click on BLOG and you will see why their new AOS FILTER technology will boost oil production dramatically

    Sentiment: Strong Buy

  • Reply to

    Having a little battle at the approx $6.00 range

    by grindle00 Jul 31, 2014 1:00 PM
    racavalli racavalli Jul 31, 2014 2:19 PM Flag

    no battle here . . . no voume . . . no buying . . . . no selling . . . . no news . . . . dead!!!

    Sentiment: Strong Buy

  • Reply to

    Lights On? Anybody Home?

    by kiwicoast72 Jul 29, 2014 4:23 PM
    racavalli racavalli Jul 31, 2014 1:14 PM Flag

    Looks like PURE may have launched a new web site

    it's up and running just fine now and management is right on schedule with expectations into the food industry.

    I think they are getting ready to surprise very positively and very soon.

    Sentiment: Strong Buy

  • racavalli by racavalli Jul 30, 2014 11:27 PM Flag

    This new report points to the significance underlying todays's press release and could very easily spark a large advance in AMPE shares that are extremely compressed from prolonged mild selling with buying absent.

    Look for a large and protracted rally beginning soon and perhaps as early as tomorrow morning.

    Love their headline . . . ANOTE REGULATORY WIN --- HARD TO IGNORE MUCH LONGER

    Sentiment: Strong Buy

  • Reply to

    Racavalli - or anyone else

    by arikofunit101 Jul 30, 2014 1:48 PM
    racavalli racavalli Jul 30, 2014 2:18 PM Flag

    If you go back a read the press release (2012) relative to the FDA granting guidance to Ampio for the Optina pivotal trial (phase 2 b that can be pivotal based on outcome), the FDA asked Ampio to include some kidney patients. there has been no mention so far but understanding the mechanism of Optina, it is reasonable to assume that it will have a significant effect on reducing or even stopping the leaking blood vessels in the kidneys as well as the eyes. It has also been suggested by the CSO, Dr. Bar-Or that one patient in the current Optina trial was an Alzheimer's patient . . . and after a few weeks of taking Optina, not only did his eyes get better, but his Alzheimer's was not noticeable any longer. Nobody knows why yet, but it is assumed that since the brain is also very rich in blood vessels, perhaps the Optina halted the leaking in the brain and reduced all of the short circuiting of the neurons and synapses.

    Optina (repurposed Danazol) works instantaneously to repair the cortical F-Actin ring structure of the cells making up the lining of the blood vessels. When this ring structure (cytoskeletal structure) breaks down as in the case of DME and diabetic nephropathy (kidneys) the tiny anchors that latch on to the ring structure to keep the cells from drifting apart, come looses and the cells drift apart and create permeability or leakage. It has been found that ultra small doses (between 20 to 40 mg) instantaneously repair the f-actin cortical ring structure and allow the fasteners to once again stabilize these cells. This stops the leaking immediately which is why the patients in the current Optina trial experienced fast visual improvement and fast degradation when they stopped taking the pill.

    Optina is going to be a very large drug . . . and it has no significant adverse side effects.

    And it is a pill

    And it is cheap.

    MEdicare iand private carriers are going to love Optina and Ampion and most likely ORP and NCE001.

    Sentiment: Strong Buy

  • Reply to

    One "take away" I get from todays PR is...

    by oldfrothingslosh Jul 30, 2014 9:18 AM
    racavalli racavalli Jul 30, 2014 11:36 AM Flag

    I have been extremely close to the markets since 1967 and market cap, share price and investor following are DEFINITELY a function for a sharp CEO. All successful companies in the market have ALWAYS focused on well crafted press releases and high profile PR.

    Market demand is UNQUESTIONABLY controlled primarily be decisions made by the CEO and Chairman.

    Nobody can blame poor share performance on anything but management's ability to execute in the the marketplace as well as in the business world.

    Having a successful high profile stock is not an accident!

    Sentiment: Strong Buy

  • racavalli by racavalli Jul 30, 2014 11:29 AM Flag

    REGN gained over $2B market cap on DME approval.

    That would equate to a rise of over $30 per share of AMPE just for Optina approval.

    Optina has high potential for approval for DME.

    It's a pill and not an injection
    It will not be nearly as expensive as Eylea or Lucentis
    It has no adverse side effects
    Lucentis and Eylea both have serious adverse side effects and both become less efficacious after a few months of treatment

    Optina results due by year end.

    Then there is Optina for kidney failure
    Then there is Optina for blood leakage in brain
    Then there is Ampion for OAK
    Then there is Ampion for OA of other joints
    Then there is Ampion for COPD
    Then there is Ampion for Chron's Disease
    Then there is Ampion for cartilage regeneration
    Then there is Ampion stem cell therapy
    Then there is Zertane
    Then there is Zertane ED for PE and ED
    Then there is NCE001 for breast cancer, brain cancer, kidney cancer and other cancers
    Then there is ORP

    Shares may be cheap today, but presents a really great buying opportunity for those who have a few minutes to do their own research, make their own phone calls and confirm for themselves that Ampio is very much for real.

    Sentiment: Strong Buy

  • Reply to

    Eylea approval impact on AMPE

    by stkanlyzr Jul 29, 2014 7:39 PM
    racavalli racavalli Jul 29, 2014 11:37 PM Flag

    I have studied both drugs closely and have even spoken at great length with the inventor, Dr. Bar-Or. I have also read far too many comments from physicians claiming Eylea and Lucentis don't work very well and any benefits do not last very long . . . and the side effects are bad.

    And they are very expensive compared to what Optina will be as a pill.

    Between the very poor efficacy of Eylea and the serious adverse SE, and understanding the vast difference in the mechanism of action of both drugs, Optina actually repairs the leaking blood vessels by correcting the damaged cytoskeletal structure in the cells making up the blood vessel lining. Anti VEGF drugs simply will never do the job right.

    Also, Optina is a pill rather than an injection and has virtually no adverse side effects. Read the cover story in Retina Today titled, "Oral Danazol For DME". It explains the mechanism clearly. Based on reading the comments for the past 2 years, t appears that nobody has read the actual report yet. Based on many uniformed comments, it also appears there is very little understanding about how important Optina can be blood rich organs such as eyes, kidneys and brains.

    Optina is going to be a giant blockbuster for several indications . . . and it has NO ADVERSE SIDE EFFECTS.

    The REGN/Eylea advocates will bash Optina every chance they get, but I predict it will completely derail Eylea sooner than most investors realize.

    Just watch as they jump all over my comments with trash talk.

    Ampio is a steal and the only investors who seem to know it are the big pharma companies that are going to make a bid for the whole company probably late this year when the BLA is filed for Ampion. They will be getting a steal! And Ampio is a steal today!

    Sentiment: Strong Buy

  • Reply to

    MHCC

    by rifleman5779 Jul 25, 2014 5:44 PM
    racavalli racavalli Jul 27, 2014 2:05 PM Flag

    I have looked into MHCC and management very closely. Their model is lightyears ahead of the industry and they are actually delivering on all of their forecasts.

    The last count indicated 1,300 locations under contract and the number appears to be growing exponentially.

    The company has no debt because they recently paid it all off.

    They are now beginning to roll out their diagnostics to their customers and be year end should be reporting very attention getting numbers.

    This company can't miss and will become a very large factor in healthcare because their business model is so well thought out, it provides what is needed by Medicare, private carriers, patients and physicians.

    Management is laser focused and delivering without missing a beat.

    They have enough cash to move forward and will supplement when need but will not have any difficulty because they are already generating revenues and have signed orders in hand that will be easy to fill.

    Shares are an exceptionally strong buy.

    Sentiment: Strong Buy

  • Reply to

    Here is a question for anyone, phhh

    by ri66 Jul 26, 2014 7:00 PM
    racavalli racavalli Jul 27, 2014 11:23 AM Flag

    Marketing is extremely important . . . but just imagine how easily Ampion can go VIRAL.

    The senior and even younger population is closely tied together via family, friends, twitter, facebook, texts and emails. With historical results from ampion, word will spread exceptionally fast and patients will be aggressively seeking treatment.

    With everything I have heard about Ampion, that is what is most likely to occur

    I believe sales are going to surprise very big and on the upside.

    I think the same thing is true of Optina.

    Sentiment: Strong Buy

  • Reply to

    Here is a question for anyone, phhh

    by ri66 Jul 26, 2014 7:00 PM
    racavalli racavalli Jul 26, 2014 9:16 PM Flag

    Shares that find themselves in huge demand ARE always found.

    The price will trade higher, but the demand will ALWAYS be met with supply from existing shareholders willing to take profits and a large number of shares from SHORT SELLERS.

    ALWAYS!

    With big news that is expected, it would not be surprising to see AMPE trade over 10 million shares.

    Companies frequently trade more than their outstanding capitalization in just a few days.

    When AMPE announces positive results from Optina, Ampio, NCE001 and cartilage regeneration, trading volume could easily break 50 million in two days.

    Cesca Therapeutics (KOOL) only less than 30 million shares outstanding when they announced their CLI trial results this February and shares traded from an average 90 day volume of 100,000 to over 50,000,000 in just 2 days.

    The big move up for Ampio will come from LONG BUYERS and not the short covering.

    Too much is being made of Ampio's short position that is really very mediocre and certainly not even attention getting.

    Ampion FINAL RESULTS due in the next week or two or three should be enough to cause almost every institution to start buying and that will send shares to very very high prices.

    The big buying will come from the long buyers.

    Sentiment: Strong Buy

  • Reply to

    Short Interest

    by billwilliams836 Jul 26, 2014 11:35 AM
    racavalli racavalli Jul 26, 2014 12:21 PM Flag

    Investors take long-term positions for the following reasons:

    1. There is a HUGE LONG-TERM CAPITAL GAINS advantage.

    2. Long-term investors typically make far more money than short-term traders.

    3. Less work and less brain damage.

    SHORT positions have no tax advantages because they are ALWAYS taxed at the FULL RATE.

    There is no advantage to remaining short for the long-term, and short traders are in and out relatively quickly.

    They may be short one day, flat the next. They may even turn around and go long if they are true traders.

    Short positions are constantly rotating and somebody who is short today will flatten out tomorrow and then put out more shares at the next rally.

    With the cost of money and the high cost of option premiums to hedge, it is highly unlikely the preponderance of short positions are anything more than short term.

    Sentiment: Strong Buy

  • SDC is a unique antimicrobial that no other can compete with because it is extremely safe, extremely effective, competitively priced . . . and it is the ONLY antimicrobial that keeps on working for 24 hours AFTER IT DRIES.

    Once sales get going, they will grow very fast because the need is enormous and in the multi billions.

    This management team has been seriously moving forward since the day they were installed and judging by news releases and dates, it appears they are ready to deliver the results very soon that will push share prices much higher.

    There appear to be a few active posters on this message board who are mostly ignored because they are clearly destructive personalities that make negative comments with no basis or no understanding of the current situation.

    They make absolutely no sense at all, they are purely emotional, and should be ignored.

    Recommend shares as VERY STRONG BUY and HOLD

    Sentiment: Strong Buy

  • Reply to

    I'm not endorsing the stock

    by desertdawglives Jul 22, 2014 11:46 PM
    racavalli racavalli Jul 24, 2014 3:39 PM Flag

    I use the product every day and my 45 years of extensive securities markets experience tells me that PURE is very close to hitting a big one out of the park.

    Shares are undervalued and will be a great performer in ay portfolio.

    Sentiment: Strong Buy

  • racavalli racavalli Jul 23, 2014 2:21 PM Flag

    thats why the shorts are covering now. they appear to be the only buyers and are placing their bids below the market to take advantage of the sellers

    Sentiment: Strong Buy

  • Reply to

    today's news

    by wiser_2000 Jul 23, 2014 1:39 PM
    racavalli racavalli Jul 23, 2014 1:52 PM Flag

    my guess is that since the shorts are substantially more sophisticated about share prices than long investors, and since volume has been substantial on the way down . . . THAT THE SHORTS HAVE BEEN THE PRIMARY BUYERS. they may be the only buyers as they continue to cover and get out and get ready to sell short at higher prices soon.

    shorting in ampio has been exceptionally profitable and will continue until the volume gets too big

    right now the volume is tiny and extremely easy to manipulate

    long investors can't figure it out yet!

    guess they need a big hammer over the head . . . like the ampion results

  • Reply to

    More bullish than anyone but WTH

    by investorgenius Jul 23, 2014 10:31 AM
    racavalli racavalli Jul 23, 2014 10:55 AM Flag

    That doesn't change until trading volume gets too big to handle for the short interests.

    And volume doesn't change until a major announcement is made or until about a week before when frontrunners will begin buying in anticipation of the announcement.

    Results are due in about the next 2 to 3 weeks, and based on earlier trials, results were strong enough that the FDA called them "Robust".

    Strong results, coupled with the current validation by two large bankers are all that is needed to send Ampio shares into a whole new world.

    Looks like Ampio is about to graduate!

    Sentiment: Strong Buy

  • Reply to

    Creeping up.......

    by mrblueeyeysnj1970 Jul 22, 2014 3:47 PM
    racavalli racavalli Jul 23, 2014 10:26 AM Flag

    Their growth story is slowly getting out and it is jaw-dropping.

    I have never, in 40 years, seen a growth rate like this in terms of revenues.

    And their revenues are very high margin that will produce very high net income

    Sentiment: Strong Buy

  • racavalli racavalli Jul 22, 2014 11:58 AM Flag

    Autologous stem cell transplants have been immensely successful in a host of indications from cardiovascular to orthopedic and even to neurological and blood cancers.

    Cesca Therapeutics (KOOL) has the leading edge over the competition because their harvesting techniques and equipment deliver far more healthy stem cells than traditional harvesting methods that cause the loss of a high percentage of stem cells.

    IF AMPION CAN ELIMINATE THE HARVEST STEP BY USING AMPION, AND IF AMPION CAN RECRUIT ENOUGH STEM CELLS TO THE DAMAGED TISSUE TO BE EFFECTIVE, THEN IT IS POSSIBLE THAT AMPION MAY EVENTUALLY BECOME THE STANDARD FOR STEM CELL THERAPIES.

    That is a very big if, but based on OAK trial results, it does appear that Ampion does indeed cause regeneration due to its recruitment of stem cells to the targeted area. Proof will be established at the conclusion of the current trial underway to demonstrate cartilage regeneration.

    The big question will be . . . just how effective does Ampion recruit stem cells compared to current autologous stem cell harvesting?

    Allogenic is not a serious contender because transplants from different subjects are likely to cause undesired immune responses.

    Ampion will very likely become a highy valuable asset for OAK treatment, but if it is proven to cause regeneration from stem cell recruitment, all bets are off and the price of AMPE will become unimaginable.

    Sentiment: Strong Buy

  • racavalli racavalli Jul 22, 2014 10:36 AM Flag

    This is setting up a major play as the food industry is enormous and the need for SDC is great.

    The FDA process they are seeking is not a lengthy one like pharmaceutical trials and SDC already has the safest rating possible by the EPA of a category IV.

    Shares are very cheap today.

    Sentiment: Strong Buy

AMPE
5.70-1.76(-23.59%)10:27 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.